<code id='D938299515'></code><style id='D938299515'></style>
    • <acronym id='D938299515'></acronym>
      <center id='D938299515'><center id='D938299515'><tfoot id='D938299515'></tfoot></center><abbr id='D938299515'><dir id='D938299515'><tfoot id='D938299515'></tfoot><noframes id='D938299515'>

    • <optgroup id='D938299515'><strike id='D938299515'><sup id='D938299515'></sup></strike><code id='D938299515'></code></optgroup>
        1. <b id='D938299515'><label id='D938299515'><select id='D938299515'><dt id='D938299515'><span id='D938299515'></span></dt></select></label></b><u id='D938299515'></u>
          <i id='D938299515'><strike id='D938299515'><tt id='D938299515'><pre id='D938299515'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:comprehensive    Page View:183

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In